38 results about "Acinetobacter infections" patented technology

The invention provides a preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as a preparation and a kit. The preparation method is characterized by comprising the following steps of: preparing antigen liquor, immunizing hens, and separating and purifying the IgY. In-vivo and in-vitro experiments prove that the prepared specificity IgY has specific binding activity to the acinetobacter baumannii, can be used for effectively inhibiting the growth of the acinetobacter baumannii and alleviating a toxic effect generated by the acinetobacter baumannii, can be applied to prevention, treatment and diagnostic analysis on infectious diseases and complications of the acinetobacter baumannii, and has wide application prospect.

The invention discloses a multiple touchdown PCR (polymerase chain reaction) detection kit capable of quickly detecting acinetobacter baumannii in lower respiratory tract specimens, belonging to the technical field of molecular diagnosis of infectious diseases of lower respiratory tracts and aiming to solve quick diagnosis of acinetobacter baumannii in lower respiratory tract specimens. The kit comprises 10*PCR buffer solution, MgCl2, dNTP, TaqDNA polymerase, BSA (bovine serum albumin), acinetobacter baumannii positive control DNA and three pairs of acinetobacter baumannii primers. The invention discloses the multiple touchdown PCR detection kit and a detection method capable of detecting acinetobacter baumannii and adopts agarose gel electrophoresis to detect the PCR products. The multiple touchdown PCR detection kit and the detection method have the advantages of quickness, simpleness and convenience, specificity and sensitivity and can be used for quick diagnosis and epidemiological survey of acinetobacter baumannii infection.

The invention discloses a method for screening a drug which is resistant to pan-drug-resistant acinetobacter baumannii by using caenorhabditis elegans. First, a caenorhabditis elegans-pan-drug-resistant acinetobacter baumannii infection model used for screening the efficacy of a composition is constructed, wherein caenorhabditis elegans has double gene mutation of glp-4 and sek-1, the culture medium of the caenorhabditis elegans-pan-drug-resistant acinetobacter baumannii co-culture consists of 20% of BHI, 5-20[mu]m of nalidixic acid and 5-20[mu]g / ml of FeCl3; the concentration of the pan-drug-resistant acinetobacter baumannii is 1*10<6>-1*10<9>CFU / mL; the duration time of the bacterial infection on the caenorhabditis elegans is 6-12 hours; and the time of the treatment on an infected modelby a drug is 24-48 hours. The model can be used for fast and high-throughput screening of in-vivo antibacterial activity of various compounds or drugs or compositions, and compared with an in-vivo animal infection model, the model has the huge advantages of low preparation cost, short period and easy operation. Compared with an in vitro model, the model can be used to screen out compounds which have large in-vivo toxicity, poor metabolism and low in vitro-in vivo correlation.

The invention discloses application of a cecropin-derived peptide in preparing a medicament for resisting Acinetobacter baumannii infection. An amino acid sequence of the cecropin-derived peptide is shown as a SEQ ID No.1. The invention also provides a bacteriostatic drug comprising the cecropin-derived peptide shown in the SEQ ID No.1 and used for inhibiting Acinetobacter baumannii. The inventionalso provides an anti-inflammatory drug including the cecropin-derived peptide shown in the SEQ ID No.1, wherein the inflammation is induced by infection with Acinetobacter baumannii. The cecropin-derived peptide of the present invention can be used to prepare the drug against Acinetobacter baumannii infection, has a small molecular weight, a low production cost, and is also resistant to drug-resistant bacteria.

The invention discloses application of arrowshaped tinospora root extractive in preparation of an antagonizing drug-resistant acinetobacter baumannii drug. A nematode model infected with drug-resistant acinetobacter baumannii is used for treatment research, a result shows that the arrowshaped tinospora root extractive has a good internal bactericidal effect on the drug-resistant acinetobacter baumannii, a good preliminary research basis is provided for researching and developing the novel antagonizing drug-resistant acinetobacter baumannii drug, and the daylight is brought for solving the problem that no drug is available for clinically drug-resistant acinetobacter baumannii infection. The arrowshaped tinospora root extractive is used for preventing and curing the drug-resistant acinetobacter baumannii, the method is rapid, price is low, and the operation is convenient and fast.

The invention discloses an application of a pseudobulubs cremastrae seu pleiones extract in preparation of an anti-drug resistant Acinetobacter baumannii drug. The application utilizes the pseudobulubs cremastrae seu pleiones extract to treat the nematode infected with the drug-resistant Acinetobacter baumannii, and shows that the pseudobulubs cremastrae seu pleiones extract has a good bactericidal effect on the drug-resistant Acinetobacter baumannii. The application provides a good preliminary research basis for the development of new anti-drug resistant Acinetobacter baumannii drugs, and brings a dawn to solve the dilemma of no available medicine clinically for drug-resistant Acinetobacter baumannii infection, the pseudobulubs cremastrae seu pleiones extract is used for prevention and treatment of the drug-resistant Acinetobacter baumannii, the method is fast, the price is cheap, and the operation is convenient.

Provided is an antibacterial composition against Acinetobacter. Provided are: a pharmaceutical composition which is for treating or preventing Acinetobacter infection, contains a complex in which lysozyme and chitosan are bound, and has an antibacterial property against Acinetobacter; and a pharmaceutical composition which is for treating or preventing Acinetobacter infection and contains a complex in which lysozyme and chitosan are bound.

The invention discloses a method for establishing an animal model infected with Acinetobacter baumannii pneumonia. The method comprises the following steps: (1) preparing an immunosuppressive New Zealand rabbit; (2) preparing an Acinetobacter baumannii solution; (3) infecting the animal and establishing the model. The simple, rapid and efficient animal model infected with Acinetobacter baumannii pneumonia is established to help people research production and development processes of drug resistance of Acinetobacter baumannii and drug resistance related mechanisms of the Acinetobacter baumannii, assistance is provided for delaying of drug resistance of bacteria and better treatment of infection with the Acinetobacter baumannii, expense for related treatment of patients can be reduced, and human health can be promoted.

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.

The invention belongs to the field of biomedicine, and particularly relates to a compound containing cyclohydroxamic acid as well as a preparation method and an application of same. The structural general formula of the compound containing cyclohydroxamic acid is shown as the specification, wherein R is one of F, Cl, Br, I,-CH3, -OCH3, -SCH3, acetyl group and cyanate radical; R1 is H, -CH3, -(CH2)nCH3, a benzene ring and an aromatic ring that has any one of F, Cl, Br, I, O, OH, -CH3, -OCH3, and cyano group; wherein the n is an integer from 1 to 8; and R2 is one of a C1-C14 chain substituent group, hydrogen, allyl, alkenebutyl, benzyl, aromatic ring, and one of benzyl group and sulphonyl group having a substituent group. According to the compound, acinetobacter baumannii infection can be reduced by inhibiting a biological membrane, the occurrence probability of infectious diseases is reduced from the source, and side effects are few. The compound also has good exopolysaccharide inhibition capability and is non-toxic.

The invention discloses a method for screening drugs against pan-drug-resistant Acinetobacter baumannii by using Caenorhabditis elegans. First, a C. elegans-pan-drug-resistant Acinetobacter baumannii infection model for screening the efficacy of the composition was constructed, and the C. elegans had glp‑ 4;sek‑1 Double gene mutation; C. elegans-pandrug-resistant Acinetobacter baumannii co-culture medium consists of 20% BHI+5~20μM nalidixic acid+5~20μg / ml FeCl 3 ; The concentration of pan-resistant Acinetobacter baumannii is 1×10 6 ~1×10 9 CFU / mL; the duration of bacterial infection of C. elegans is 6-12 hours; the duration of drug treatment of infection model is 24-48 hours. The model can be used for rapid and high-throughput screening of the in vivo antibacterial activity of various compounds or drugs or compositions. Compared with the in vivo animal infection model, the model has the great advantages of low preparation cost, short cycle and simple operation. Compared with in vitro models, compounds with high toxicity in vivo, poor metabolism and low correlation between in vitro and in vivo can be screened out.

The invention provides a combined medicine for inhibiting formation of a ubiquitous drug-resistant acinetobacter baumannii biofilm. The combined medicine contains baicalin and tigecycline which are prepared from the same or different specification units and used for simultaneous or separate administration, and a pharmaceutically acceptable carrier. Experimental results show that compared with the single use of baicalin or tigecycline, the combined use of baicalin and tigecycline significantly improves the effect of the drug in inhibiting the formation of the XDRAB biofilm. The combined medicine provided by the invention has a remarkably improved effect of inhibiting the formation of an XDRAB biofilm, can reverse the drug resistance of XDRAB and reduce the toxicity of XDRAB, and has a wide application prospect in the preparation of anti-ubiquitous drug-resistant Acinetobacter baumannii medicines and medicines for preventing and treating diseases caused by ubiquitous drug-resistant Acinetobacter baumannii infection.

The invention discloses a composition for treating carbapenem antibiotic resistant acinetobacter baumannii infection. The inventor studies and finds that a combination of sulbactam and ceftazidime ina specific ratio has an excellent treatment effect on CR-Ab infection, and the treatment effect of the combination is even better than that of a composition of carbapenem and sulbactam.

The present invention relates to the effect of Chaihu Guizhi Decoction combined with tigecycline in the treatment or prevention of pneumonia, especially the effect in the treatment of leukopenic Acinetobacter baumannii pneumonia, using a rat model of leukopenic Acinetobacter baumannii pneumonia, To provide reference for clinical treatment of Acinetobacter baumannii infection.